Opioid and chronic non-cancer pain

Journal of Anaesthesiology Clinical Pharmacology

Volumn 29, Issue 1, 2013, Pages 6-12

  Gupta, Sameer ^a   Atcheson, Robert ^a  

^a NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Chronic non cancer pain; musculoskeletal pain; neuropathic pain; opioids

Indexed keywords

17 METHYLNALTREXONE; ALVIMOPAN; BUPRENORPHINE; CODEINE; CODEINE PHOSPHATE; DIAMORPHINE; DIHYDROCODEINE; FENTANYL; HYDROCODONE; HYDROMORPHONE; LAXATIVE; METHADONE; MORPHINE; NALOXONE; NARCOTIC ANALGESIC AGENT; OXYCODONE; TRAMADOL;

ANALGESIC ACTIVITY; CHRONIC NON CANCER PAIN; CONCENTRATION LOSS; CONFUSION; CONSTIPATION; DIETARY FIBER; DIZZINESS; DROWSINESS; DRUG ABSORPTION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDICATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERANCE; DRUG WITHDRAWAL; ENDOCRINE DISEASE; EVIDENCE BASED MEDICINE; FIBROMYALGIA; FOLLOW UP; GONADOTROPIN DEFICIENCY; HUMAN; HYPERALGESIA; LOW DRUG DOSE; MEDICAL DECISION MAKING; MOOD CHANGE; NAUSEA; OPIATE ADDICTION; OUTCOME ASSESSMENT; PAIN; PATIENT COMPLIANCE; PATIENT MONITORING; PATIENT SELECTION; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PRESCRIPTION; PRURITUS; PSYCHOLOGIC ASSESSMENT; QT PROLONGATION; RESPIRATION DEPRESSION; REVIEW; RISK BENEFIT ANALYSIS; SEDATION; SIDE EFFECT; SLEEP DISORDERED BREATHING; SUDDEN DEATH; SWEATING; TORSADE DES POINTES; TRAVEL; TREATMENT DURATION; VOMITING;

EID: 84873478022     PISSN: 09709185     EISSN: 22312730     Source Type: Journal    
DOI: 10.4103/0970-9185.105784     Document Type: Review

References (45)

1. Trescot AM, Helm S, Hansen H, Benyamin R, Glaser SE, Adlaka R, et al. Opioids in the management of chronic non-cancer pain: An update of American Society of the Interventional Pain Physicians' (ASIPP) Guidelines. Pain Physician 2008;11:S5-62.
2. The British Pain society. Opioids for persistent pain: Good practice. A consensus Statement. Jan 2010. Available from: http://www. britishpainsociety. org/book-opioid-main.pdf [Last accessed on 2011 Nov 20].
3. Furlan AD, Reardon R, Weppler C. National Opioid Use Guideline Group. Opioids for chronic noncancer pain: A new Canadian practice guideline. Can Med Assoc J 2010;182:923-30.
4. Dworkin RH, O'Connor AB, Audette J, Baron R, Gourlay GK, Haanpää ML, et al. Recommendations for the Pharmacological Management of Neuropathic Pain: An Overview and Literature Update. Mayo Clin Proc 2010;85:S3-14.
5. Dworkin RH, O'Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, et al. Pharmacologic management of neuropathic pain: Evidence-based recommendations. Pain 2007;132:237-51.
6. Moulin DE, Clark AJ, Gilron I, Ware MA, Watson CPN, Sessle BJ, et al. Pharmacological management of chronic neuropathic pain-Consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag 2007;12:13-21.
7. Ballantyne JC, Shin NS. Efficacy of opioids for chronic pain. Clin J Pain 2008;24:469-78.
8. Eriksen J, Sjøgren P, Bruera E, Ekholm O, Rasmussen NK. Critical issues on opioids in chronic non-cancer pain: An epidemiological study. Pain 2006;125:172-9.
9. Dhalla IA, Persaud N, Juurlink DN. The prescription opioid crisis. BMJ 2011;343:d5142.
10. Dunn KM, Saunders KW, Rutter CM, Banta-Green CJ, Merrill JO, Sullivan MD, et al. Opioid prescription for chronic pain and overdose. A cohort study. Ann Intern Med 2010;152:85-92.
11. Cahill CM, Taylor A. A piece of the puzzle is revealed for delta opioid receptor-mediated analgesia. Pain 2011;152:1217-8.
12. Gaveriaux-Ruff C, Nozaki C, Nadal X, Hever XC, Weibel R, Matifas A, et al. Genetic ablation of delta opioid receptors in nociceptive sensory neurons increases chronic pain and abolishes opioid analgesia. Pain 2011;152:1238-48.
13. Yue QY, Hasselström J, Svensson JO, Säwe J. Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: Comparisons between extensive and poor hydroxylators of debrisoquine. Br J Clin Pharmacol 1991;31:635-42.
14. Felden L, Walter C, Harder S, Treede RD, Kayser H, Drover D, et al. Comparative clinical effects of hydromorphone and morphine: A meta-analysis. Br J Anaesth 2011;107:319-28.
15. McNicol ED, Haroutiunian S, Lipman AG. Methadone for chronic non-cancer pain in adults (Protocol). Cochrane Database Syst Rev 2009;4:CD008025.
16. Cruciani RA, Sekine R, Homel P, Lussier D, Yap Y, Suzuki Y, et al. Measurement of QTc in Patients Receiving Chronic Methadone Therapy. J Pain Symptom Manage 2005;29:385-91.
17. Krantz MJ, Lewkowiez L, Hays H, Woodroffe MA, Robertson AD, Mehler PS. Torsade de Pointes Associated with Very-High-Dose Methadone. Ann Intern Med 2002;137:501-4.
18. Chugh SS, Socoteanu C, Reinier K, Waltz J, Jui J, Gunson K. A Community-Based evaluation of sudden death associated with therapeutic levels of methadone. Am J Med 2008;121:66-71.
19. Ballantyne JC, Carwood C. Comparative efficacy of epidural, subarachnoid, and intracerebroventricular opioids in patients with pain due to cancer. Cochrane Database Syst Rev 2005;1:CD005178.
20. Ballantyne JC. Opioids around the clock? Pain 2011;152:1221-2.
21. Von Korff M, Merrill JO, Rutter CM, Sullivan M, Campbell CI, Weisner C. Time-scheduled vs. pain-contingent opioid dosing in chronic opioid therapy. Pain 2011;152:1256-62.
22. Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E. Opioids for chronic non cancer pain: A meta-analysis of effectiveness and side effects. Can Med Assoc J 2006;174:1589-94.
23. Camilleri M. Opioid-Induced Constipation: Challenges and Therapeutic Opportunities. Am J Gastroenterol 2011;106:835-42.
24. McNicol E, Horowicz-Mehler N, Fisk RA, Bennett K, Gialeli-Goudas M, Chew PW, et al. Management of opioid side effects in cancer-related and chronic noncancer pain: A Systemic Review. J Pain 2003;4:231-56.
25. Tamayo AC, Diaz-Zuluaga PA. Management of opioid-induced bowel dysfunction in cancer patients. Support Care Cancer 2004;12:613-8.
26. Leppert W. The role of opioid receptor antagonists in the treatment of opioid-induced constipation: A review. Adv Ther 2010;27:714-30.
27. Smith K, Hopp M, Mundin G, Bond S, Bailey P, Woodward J, et al. Naloxone as part of a prolonged release oxycodone/naloxone combination reduces oxycodone-induced slowing of gastrointestinal transit in healthy volunteers. Expert Opin Investig Drugs 2011;20:427-39.
28. Fishbain DA, Cutler RB, Rosomoff HL, Rosomoff RS. Can patients taking opioids drive safely? A structured evidence-based review. J Pain Palliat Care Pharmacother 2002;16:9-28.
29. Fishbain DA, Cutler RB, Rosomoff HL, Rosomoff RS. Are opioid-dependent/tolerant patients impaired in driving-related skills? A structured evidence-based review. J Pain Symptom Manage 2003;25:559-77.
30. Kress HG, Kraft B. Opioid medication and driving ability. Eur J Pain 2005;9:141-4.
31. Lee M, Silverman SM, Hansen H, Patel VB, Manchikanti L. A Comprehensive Review of Opioid-Induced Hyperalgesia. Pain Physician 2011;14:145-61.
32. Mao J. Opioid-Induced Hyperalgesia. IASP Pain Clin Updat 2008;16:1-4.
33. Fraser LA, Morrison D, Morley-Forster P, Paul TL, Tokmakejian S, Larry Nicholson R, et al. Oral Opioids for Chronic Non-cancer Pain: Higher Prevalence of Hypogonadism in Men than in Women. Exp Clin Endocrinol Diabetes 2009;117:38-43.
34. Aloisi AM, Ceccarelli I, Carlucci M, Suman A, Sindaco G, Mameli S, et al. Hormone replacement therapy in morphine-induced hypogonadic male chronic pain patients. Reprod Biol Endocrinol 2011;9:26.
35. Reddy RG, Aung T, Karavitaki N, Wass JA. Opioid induced hypogonadism. BMJ 2010;341:c4462.
36. Smith HS, Elliott JA. Opioid-Induced Androgen Deficiency (OPIAD). Pain Physician 2012;15:ES145-56.
37. United Nations. Report of the International Narcotics Control Board for 2009. Available from: http://www.incb.org/pdf/annual-report/2009/en/AR-09.[Last accessed on 2012 Sep 3].
38. Raith K, Hochhaus G. Drugs used in the treatment of opioid tolerance and physical dependence: A review. Int J Clin Pharmacol Ther 2004;42:191-203.
39. Jensen MK, Thomsen AB, Højsted J. 10-year follow-up of chronic non-malignant pain patients: Opioid use, health related quality of life and health care utilization. Eur J Pain 2006;10:423-33.
40. Watson CP, Watt-Watson JH. Chronic non cancer pain and the long term utility of opioids. Pain Res Manage 2004;9:19-24.
41. Webster LR, Webster RM. Predicting aberrant behaviours in opioid treated patients: Preliminary validation of the opioid risk tool. Pain Med 2005;6:432-42.
42. Ballantyne JC, LaForge KS. Opioid dependence and addiction during opioid treatment of chronic pain. Pain 2007;129:235-55.
43. Vadalouca A, Moka E, Argyra E, Sikioti P, Siafaka I. Opioid rotation in patients with cancer: A review of the current literature. J Opioid Manag 2008;4:213-50.
44. Lange B, Kuperwasser B, Okamoto A, Steup A, Häufel T, Ashworth J, et al. Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain. Adv Ther 2010;27:381-99.
45. Home Office. Personal licences. Available from: personal/?view=Standard [Last accessed 2011 Nov 20].